CX3CL1 and ischemia: In fact, over the past decade, remarkable advances have been made in understanding and elucidating the phenomenon of the immunosuppressive and neuroprotective potency of fractalkine signaling in a number of different experimental models, including focal and global, transient or permanent ischemia.